Joint with: Immune Cell Therapies: Advances in Cancer and Autoimmune Disease
Cancer Immunotherapy: Clinical Lessons to New Modalities

Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers: Christian U Blank, Stefani Spranger and Anna Christina Obenauf

  In Person
  On Demand

Mar 16–19, 2025 | Fairmont Banff Springs, Banff, AB, Canada
Scientific Organizers: Christian U Blank, Stefani Spranger and Anna Christina Obenauf

Supported by:
Available Formats:   = In Person     = On Demand
Sunday, March 16, 2025
Registration
4:00–8:00 PM
 Van Horne Foyer
Welcome Mixer
6:00–8:00 PM
 Van Horne Foyer
Monday, March 17, 2025
Breakfast
7:00–8:00 AM
 Mezzanine 2
Welcome and Keynote Session (Joint)
8:00–9:30 AM
 Van Horne Ballroom
Carl H. June, University of Pennsylvania
Cell Therapies: Current State of the Art
Ton N. Schumacher, Netherlands Cancer Institute
Dissecting T Cell Recognition of Cancer
Coffee Break
9:30–9:50 AM
 Van Horne Foyer
Award Recipient Acknowledgement
9:50–9:55 AM
 Van Horne Ballroom
Overcoming Challenges in Immune and Cell Therapy: Insights into Mechanisms of Failure and Solutions (Joint)
9:55–12:00 PM
 Van Horne Ballroom
Nathan Singh, Washington University School of Medicine
Genomic Regulation of CAR T Cell Driven Dysfunction
Shannon J Turley, Genentech, Inc.
CAF Targeting
Anna Christina Obenauf, Research Institute of Molecular Pathology
Rational Combination Therapies to Stimulate the APC Compartment
May Daher, MD Anderson Cancer Center
Metabolic Interventions to Enhance Adoptive Cellular Therapies
Poster Setup
12:00–1:00 PM
 Mezzanine 2
On Own for Lunch
12:00–2:30 PM
Poster Viewing
1:00–10:00 PM
 Mezzanine 2
Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
 Van Horne A
Lauren E Milling, Harvard Medical School
A STUB1-CHIC2 Complex Decreases IL-27Rα Expression on CD8+ T Cells To Restrain Tumor Immunity
Alice O Kamphorst, Icahn School of Medicine at Mount Sinai
ICOS Limits Memory-like Properties and Function of Exhausted PD-1+ CD8 T Cells
Derek A Wainwright, Loyola University Chicago Stritch School of Medicine
IDO1 - Revising Dogma to Improve Control
Henrique Borges da Silva, Mayo Clinic Arizona
The eATP Receptor P2RX7 Promotes Optimal Progenitor Exhausted CD8+ T Cell Responses To Anti-PD1 Blockade
Coffee Available
4:30–5:00 PM
 Van Horne Foyer
DC and Alternative Immune Cell Activation
5:00–7:00 PM
 Van Horne A
Matthew F Krummel, University of California, San Francisco
Immune Archetypes
Susan M Kaech, The Salk Institute
Metabolic Control of Anti-Tumor Immunity
Cansu Cimen Bozkus †, Icahn School of Medicine at Mount Sinai
Talk Title to Be Announced
Joanna Pozniak, VIB
Short Talk: Cytotoxic NK Cells Impede Response to Checkpoint Immunotherapy in Melanoma With an Immune-Excluded Phenotype
Fiona Chatterjee, Massachusetts Institute of Technology
Short Talk: Tumor-resident CD103+ CD11b+ Dendritic Cells are Associated with Poor Anti-Tumor Immunity in Ovarian Cancer
Social Hour with Lite Bites
7:00–8:00 PM
 Mezzanine 2
Posters
7:30–10:00 PM
 Mezzanine 2
Tuesday, March 18, 2025
Breakfast
7:00–8:00 AM
 Mezzanine 2
Neoadjuvant Cancer Immunotherapy, Where are We Standing
8:00–11:00 AM
 Van Horne A
Tina Cascone, University of Texas MD Anderson Cancer Center
Neoadjvant Cancer Immunotherapy in NSCLC
Christian U Blank, Netherlands Cancer Institute - NKI-AVL
Personalized Neoadjuvant Cancer Immunotherapy in Melanoma
Laurence Buisseret †, Institut Jules Bordet, Hôpital
Talk Title to be Announced
Philip Georg Demaerel, UZLeuven
Short Talk: Insights from Single-Cell Resolution Spatial Transcriptomic Analysis Before and During Neoadjuvant Immunotherapy in Advanced Melanoma
Nicholas J Salgia, Roswell Park Comprehensive Cancer Center
Short Talk: Untangling and Applying the Paradoxical Immune Sensitivity of Sarcomatoid Renal Cell Carcinoma
Jaroslav Zak, The Scripps Research Institute
Short Talk: Mechanistic Insights into the Paradoxical Efficacy of JAK and PD1 Inhibition in Cancer Immunotherapy
Coffee Break
9:00–9:20 AM
 Van Horne Foyer
Poster Setup
11:00–1:00 PM
 Mezzanine 2
On Own for Lunch
11:00–5:00 PM
Poster Viewing
1:00–10:00 PM
 Mezzanine 2
Career Roundtable (Joint)
3:00–4:30 PM
 Van Horne B/C
Coffee Available
4:30–5:00 PM
 Van Horne Foyer
Integrative Strategies in Cancer Immunotherapy: Harnessing Myeloid Cells, NK Cells, Unconventional T Cells and More
5:00–7:00 PM
 Van Horne A
Stefani Spranger, Massachusetts Institute of Technology
DC Determine Quality of T Cell Responses
Wolfgang Karl Kastenmueller, Universität Würzburg
Affinity Selection Phase during CD8 T Cell Priming
Ann F. Cheung, Dragonfly Therapeutics
NK Cell Therapeutics
Chenyu Zhang, University of California, Berkeley
Short Talk: Intra-tumoral Treg Ablation Activates a CD4-NK Cell Axis to Control MHC Class I-deficient Tumors
Richard P. Tobin, University of Colorado Anschutz Medical Campus
Short Talk: Alterations in MAIT Cells Frequency and Function During Melanoma Development and Treatment
Social Hour with Lite Bites
7:00–8:00 PM
 Mezzanine 2
Posters
7:30–10:00 PM
 Mezzanine 2
Wednesday, March 19, 2025
Breakfast
7:00–8:00 AM
 Mezzanine 2
Cytokine/Chemokine Biology and Engineering
8:00–11:00 AM
 Van Horne A
Jamie Spangler, Johns Hopkins University
Cytokine Engineering
Joanna R Groom, Walter and Eliza Hall Institute of Medical Research
Chemokine Signaling and Positioning in the LN
Howard L. Kaufman, Massachusetts General Hospital and Ankyra Therapeutics
Anchored Cytokines for the Treatment of Cancer
Sameer Chopra, Werewolf Therapeutics Inc.
Short Talk: Unmasking the Potential of Cytokines for Cancer Immunotherapy: Lessons Learned from the Early Clinical Development of Tumor-activated IL-2 and IL-12 INDUKINE Molecules
Christopher Harvey
Short Talk: AI/ML-Driven Discovery of a Novel Proteoglycan for Precision Targeting of Solid Tumors by T Cell Engagers
Xinyi Tu, Mayo Clinic
Short Talk: A New PD-L1 Antibody Degrades PD-L1 and Sensitizes Cancer Cells to Cytotoxic Therapy
Michelle Nathalie von Locquenghien, Weizmann Institute of Science
Short Talk: Development of Novel “Myeloid-Targeted Immunocytokine and (NK)T cell Enhancer” (MiTE) with Tumor-Conditioned Cytokine Activity for Cancer Treatment Using Single Cell Genomics and AI
Coffee Break
9:00–9:20 AM
 Van Horne Foyer
On Own for Lunch
11:00–2:30 PM
Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions
2:30–4:30 PM
 Van Horne A
Ana Marcu, Genentech
Developing Discovery Proteomics Technologies to Elucidate HLA Neoantigen Presentation
Feng Han †, DKFZ (German Cancer Research Center)
CMTM4/6 as Novel Therapeutic Targets to Sensitize Hepatocellular Carcinoma to Immunotherapy
Caitlin O'Brien-Ball, University of Oxford
Characterising Novel Protein Tools for Potentiating T Cell Activation by Inhibiting PD-1
Amanda G Heard †, University of Kansas Medical Center
Progesterone Promotes Immunosuppression in Murine Mammary Tumors by Modulating T Cell Infiltration and Function
Trevor E Frederick, Rutgers University
Elucidating The Mechanisms Of Novel Type I-Type III IFN Fusion Proteins For Cancer Therapy
Coffee Available
4:30–5:00 PM
 Van Horne Foyer
Engineering in Cancer Immunotherapy to Enhance Efficacy (Joint)
5:00–6:30 PM
 Van Horne Ballroom
Jaehyuk Choi, Northwestern University
Talk Title to be Announced
Rosandra Natasha Kaplan, NCI, National Institutes of Health
Engineering of Myeloid Cells
Julia Carnevale, University of California, San Francisco
CRISPR-Based T Cell Editing to Enhance Cell Therapy
Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (Joint)
6:30–7:00 PM
 Van Horne Ballroom
Social Hour with Lite Bites
7:00–8:00 PM
 Mezzanine 2
Entertainment
8:00–11:00 PM
Cash Bar
8:00–11:00 PM
Thursday, March 20, 2025
Departure
12:00–11:59 PM

Subscribe for Updates